{"id":"tas-120","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Stomatitis"},{"rate":null,"effect":"Nail toxicity"}]},"_chembl":null,"_fixedAt":"2026-03-30T18:04:09.724720","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TAS-120 is a selective, irreversible FGFR inhibitor that covalently binds to FGFR kinase domains, preventing downstream signaling through the MAPK and PI3K pathways. This mechanism is particularly relevant in cancers driven by FGFR alterations, including FGFR fusions, amplifications, and mutations. By inhibiting FGFR activity, TAS-120 suppresses proliferation of FGFR-dependent tumor cells.","oneSentence":"TAS-120 is a fibroblast growth factor receptor (FGFR) inhibitor that blocks FGFR signaling to suppress tumor cell growth.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:53:54.182Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cholangiocarcinoma with FGFR2 fusion or rearrangement"},{"name":"Other FGFR-altered solid tumors"}]},"_fixedFields":["sideEffects","modality→Small Molecule"],"trialDetails":[{"nctId":"NCT06506955","phase":"PHASE2, PHASE3","title":"Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.","status":"ENROLLING_BY_INVITATION","sponsor":"Taiho Oncology, Inc.","startDate":"2024-10-01","conditions":"Advanced/Metastatic Cancer","enrollment":15},{"nctId":"NCT04507503","phase":"","title":"Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements","status":"APPROVED_FOR_MARKETING","sponsor":"Taiho Oncology, Inc.","startDate":"","conditions":"Advanced Cholangiocarcinoma","enrollment":""},{"nctId":"NCT02813135","phase":"PHASE1, PHASE2","title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-08-03","conditions":"Pediatric Cancer","enrollment":472},{"nctId":"NCT04601857","phase":"PHASE2","title":"Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma","status":"TERMINATED","sponsor":"Taiho Oncology, Inc.","startDate":"2021-01-07","conditions":"Advanced and Metastatic Urothelial Cancer","enrollment":43},{"nctId":"NCT05727176","phase":"PHASE2","title":"Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement","status":"RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2023-07-05","conditions":"Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement","enrollment":120},{"nctId":"NCT05945823","phase":"PHASE2","title":"Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2023-07-13","conditions":"Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer","enrollment":53},{"nctId":"NCT06263153","phase":"PHASE2","title":"Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy","status":"RECRUITING","sponsor":"Yuanquan Yang","startDate":"2024-12-30","conditions":"Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8","enrollment":24},{"nctId":"NCT03784014","phase":"PHASE3","title":"Molecular Profiling of Advanced Soft-tissue Sarcomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2019-10-19","conditions":"Soft Tissue Sarcoma","enrollment":603},{"nctId":"NCT04828486","phase":"PHASE2","title":"Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2021-08-17","conditions":"Advanced Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma","enrollment":14},{"nctId":"NCT04024436","phase":"PHASE2","title":"A Study of TAS-120 in Patients With Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Taiho Oncology, Inc.","startDate":"2020-01-28","conditions":"Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification","enrollment":64},{"nctId":"NCT04189445","phase":"PHASE2","title":"Futibatinib in Patients With Specific FGFR Aberrations","status":"TERMINATED","sponsor":"Taiho Oncology, Inc.","startDate":"2020-08-05","conditions":"Advanced or Metastatic Solid Tumor, Advanced or Metastatic Gastric or Gastroesophageal Cancer, Myeloid or Lymphoid Neoplasms (MLN)","enrollment":115},{"nctId":"NCT02052778","phase":"PHASE1, PHASE2","title":"A Study of TAS-120 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Taiho Oncology, Inc.","startDate":"2014-07-21","conditions":"Cholangiocarcinoma, Urothelial Cancer, Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors","enrollment":407},{"nctId":"NCT04093362","phase":"PHASE3","title":"Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements","status":"TERMINATED","sponsor":"Taiho Oncology, Inc.","startDate":"2021-01-06","conditions":"Advanced Cholangiocarcinoma, FGFR2 Gene Rearrangements","enrollment":10},{"nctId":"NCT04999761","phase":"PHASE1","title":"AB122 Platform Study","status":"RECRUITING","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2021-06-01","conditions":"Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer","enrollment":917},{"nctId":"NCT04965818","phase":"PHASE1","title":"Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer","status":"TERMINATED","sponsor":"Taiho Oncology, Inc.","startDate":"2021-09-20","conditions":"Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Non-Small Cell Lung Cancer, KRAS Gene Mutation","enrollment":38},{"nctId":"NCT03767075","phase":"PHASE2","title":"A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)","status":"RECRUITING","sponsor":"Vall d'Hebron Institute of Oncology","startDate":"2018-12-10","conditions":"Advanced Solid Tumor","enrollment":1000}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"HEPATIC ENCEPHALOPATHY"},{"count":1,"reaction":"AGITATION"},{"count":1,"reaction":"ANAEMIA"},{"count":1,"reaction":"ASTHENIA"},{"count":1,"reaction":"BILE DUCT OBSTRUCTION"},{"count":1,"reaction":"CHOLANGIOCARCINOMA"},{"count":1,"reaction":"CONFUSIONAL STATE"},{"count":1,"reaction":"COUGH"},{"count":1,"reaction":"DRUG INEFFECTIVE"},{"count":1,"reaction":"GASTRIC DISORDER"}],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Futibatinib"],"phase":"phase_3","status":"active","brandName":"TAS-120","genericName":"TAS-120","companyName":"Taiho Oncology, Inc.","companyId":"taiho-oncology-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TAS-120 is a fibroblast growth factor receptor (FGFR) inhibitor that blocks FGFR signaling to suppress tumor cell growth. Used for Cholangiocarcinoma with FGFR2 fusion or rearrangement, Other FGFR-altered solid tumors.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":3,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}